Literature DB >> 30601461

Multimodality Management of Complex Periorbital Venolymphatic Malformations.

Sathyadeepak Ramesh1,2, Gary Duckwiler3, Robert A Goldberg4, Daniel B Rootman4,5.   

Abstract

PURPOSE: To review a representative case series and share a stepwise approach to the diagnosis and treatment of periorbital venolymphatic malformations.
METHODS: A case series of 9 patients with representative periorbital venolymphatic malformations. All patients managed at the University of California, Los Angeles Orbital Center for a vascular malformation over the last 5 years were reviewed. Cases representative of the varied pathologic findings and techniques were selected. The clinical, radiologic, and intraoperative findings are presented and a survey of techniques composed.
RESULTS: Venolymphatic malformations can have protean manifestations. Characteristics vital to the understanding and management of these lesions are the classification and vascular composition of the lesion, internal flow and drainage patterns, anatomic localization and association with distant components. Options for treatment include sclerotherapy, biologic therapy, embolization, surgical excision, or some combination thereof.
CONCLUSIONS: A comprehensive understanding of each patient's unique lesion is critical to a rational treatment approach. Teamwork and creativity are key to effectively managing these lesions.

Entities:  

Year:  2019        PMID: 30601461     DOI: 10.1097/IOP.0000000000001294

Source DB:  PubMed          Journal:  Ophthalmic Plast Reconstr Surg        ISSN: 0740-9303            Impact factor:   1.746


  2 in total

1.  Clinical Assessment and Lesion-Specific Management of Orbital Vascular Malformations.

Authors:  Daniel B Rootman; Stefania B Diniz; Liza M Cohen
Journal:  J Neurol Surg B Skull Base       Date:  2021-03-23

2.  A nomogram for predicting sclerotherapy response for treatment of lymphatic malformations in children.

Authors:  Zhiping Wu; Yun Zou; Ronghua Fu; Pingliang Jin; Hua Yuan
Journal:  Eur J Med Res       Date:  2022-10-21       Impact factor: 4.981

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.